The NCI, as a sponsor of
investigational drug trials, has the responsibility to assure to
the FDA that systems for drug accountability are being maintained
by investigators in its clinical trials program. The data obtained
from the drug accountability record is used to track the dispensing
of investigational anticancer drugs from receipt from NIC to
dispensing or administration to patients. NCI and/or its auditors
for compliance reasons use this information.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.